MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease

Decipher® is covered for men with localized or biochemically recurrent (non-metastatic) prostate adenocarcinoma who have a life expectancy of >= 10 years and are candidates for or considering specified management options (e.g., active surveillance vs definitive therapy, radiation ± ADT changes, post-op adjuvant/salvage decisions). Coverage requires testing on FFPE prostate biopsy tissue with ≥0.5 mm linear tumor or on FFPE resection specimen, no pelvic radiation or ADT prior to the specimen, and that results will be used to guide treatment per established guidelines; other genomic tests may be covered if MolDX verifies equivalent analytical and clinical validity.

"Decipher® is covered for men with localized or biochemically recurrent prostate adenocarcinoma (no clinical evidence of metastasis) who have a life expectancy >= 10 years and are good candidates fo..."